This patent further strengthens Biotts’ intellectual property portfolio and demonstrates our commitment to developing innovative drug delivery solutions.

Advantages of MTC-A4:

  • Lower Concentration, Effective Relief: MTC-A4 achieves comparable bioavailability with a 4% concentration of each anesthetic, compared to 7% in Pliaglis.
  • Reduced Side Effects: Lower concentration may decrease the likelihood of adverse reactions.
  • Improved Stability: MTC-A4 demonstrates more stable blood concentrations over 24 hours.
  • Enhanced Comfort: The optimized formulation minimizes irritation and discomfort.

Key Highlight:

Biotts’ proprietary transdermal drug delivery technology enables efficient and controlled permeation of the anesthetic active substances, maximizing effectiveness while minimizing systemic exposure.

Link to the patent – MTC-A4 US Patent

Interested in partnering with Biotts to explore new applications for our transdermal drug delivery technology? Contact us at info@biotts.com to discuss opportunities.